W
ith an increasing understanding of the molecular processes involved in thyroid tumorigenesis, the application of molecular tools has become particularly attractive to improve differential diagnosis of thyroid nodules (1) (2) (3) . As a result of transcriptome studies, an increasing list of candidate genes for the molecular discrimination of benign and malignant thyroid tumors is now emerging (4 -10) . However, with the exception of very few, candidate markers have been investigated only in single studies and have not been validated by independent investigators. In addition, the analyzed thyroid samples were derived from different populations (mostly from the United States and Japan), and it is unclear how far environmental factors, such as iodine supply, may influence the candidate gene expression.
In the present study, we evaluated a set of 10 recently proposed marker genes (4, 6 -8, 11 ) and investigated their diagnostic potential to distinguish benign and malignant thyroid tumors, including follicular neoplasia, in a defined population living in a region with borderline iodine deficiency. To this aim we analyzed quantitative mRNA gene expression and determined single as well as combined marker gene ratios in a series 150 thyroid specimen comprising 46 thyroid cancers, 52 benign thyroid nodules, and 52 normal thyroid tissues. 
Patients and Methods

Thyroid samples
RNA extraction and quantitative real-time PCR
Snap-frozen tissue samples were pulverized and transferred into TRIzol reagent (Invitrogen, Carlsbad, CA). RNA extraction and cDNA synthesis were carried out as described and expression of housekeeping genes [␤-actin (ACTB) and glyceraldehyde-3-phosphate dehydrogenase] was demonstrated in all samples by RT-PCR (6, 11) . Real-time PCR (LightCycler system, LightCycler-DNA Master SYBR Green I kit; Roche, Mannheim, Germany) was performed using intron-spanning primers for ADM3, B4GALT, CCND2, ETS1, HGD1, LGALS3, PCSK, PLAB, TFF3, TG, and the housekeeping gene ACTB. For each PCR annealing temperatures and MgCl 2 concentrations were optimized to create a onepeak melting curve (primer sequences for and PCR condition are available on request).
Statistical analysis
The fold difference (n) in up-or down-regulation of mRNA expression was calculated as follows: n ϭ 2(threshold cycle of normal tissue Ϫ threshold cycle of diseased tissues)/ 2(threshold cycle of ACTB (normal tissue) Ϫ threshold cycle of ACTB (diseased tissues)] Normal tissue corresponds to the surrounding tissue of toxic thyroid nodules and cold thyroid nodules for CTN, FTC, PTC, and UTC, respectively. For the molecular discrimination of benign and malignant thyroid tumors, mRNA expression levels in 28 follicular adenomas and 24 adenomatous nodules were compared with mRNA expression levels in 47 thyroid cancers (20 FTCs, 20 PTCs, and seven UTCs). For the molecular discrimination of follicular thyroid tumors mRNA expression levels in 28 follicular adenomas were compared with mRNA expression levels in 27 FTCs (including seven follicular variant PTCs). The MannWhitney U test within the SPSS software (version 11.5; SPSS, Chicago, IL) was used for statistical analysis of mRNA expression differences.
For the calculation of cancer prediction, we used the prediction analysis of microarrays (PAM), which is a statistical technique for class prediction from gene expression data using nearest shrunken centroids as described elsewhere (12) . PAM can be freely downloaded (http://www-stat.stanford.edu/ϳtibs/PAM).
Results
mRNA expression of ADM3 (7), CCND2, PLAB, PCSK2 (4),
LGALS3, TFF3 (8, 13) , B4GALT, HGD1 (6) , TG, and ETS1 (11) was demonstrated in all 150 thyroid specimens. Comparison of benign and malignant thyroid pathologies showed higher mRNA expression levels for HGD1, B4GALT, and TFF3 in benign nodules (CTN and TTN) and PLAB, LGALS3, and ADM3 in thyroid cancers (FTCs, PTCs, and UTCs). On a singlegene basis, this reached statistical significance only for Trefoil factor-3 (TFF3), prostate differentiation factor (PLAB), and adrenomedullin-3 (ADM3) ( Table 1) . Given the heterogeneity of thyroid tumors, combination of genes may very likely improve the molecular discrimination of benign and malignant thyroid pathologies. We therefore calculated two-gene ratios, based on genes, which are up-or downregulated in thyroid malignancy vs. nonmalignant thyroid specimen and normal thyroids, respectively: 1) using this approach, we identified 11 two-marker gene sets, which allowed both a distinction of benign and malignant thyroid nodules and a discrimination of follicular adenoma and carcinoma (Table 1) ; 2) of all investigated markers, down-regulation of TFF3 in malignant tumors was the best indicator for thyroid malignancy, and all TFF3-based gene ratios were significantly increased in the thyroid cancers (Table 1) ; and 3) for the discrimination of follicular adenoma and carcinoma, the best marker sets were PLAB/TFF3, PLAB/TG, LGAL3/TFF3 and ADM3/TFF3 (Fig. 1A) . Protein convertase 2 (PCSK2) was the only proposed marker (4), for which inclusion in a two-marker gene set did not confer an additional diagnostic value.
To assess the accuracy of cancer prediction we used the PAM method (12) . This nearest shrunken centroid method is based on standardization by within-class SD for each gene and has been designed to identify the smallest set of genes that can accurately classify specific disease entities. Using this approach, we found that the analysis of six genes per sample (corresponds to threshold ϭ 2) allows an acceptable prediction or exclusion of cancer (sensitivity, 0.8; specificity, 1.0; positive predictive value, 1.0; negative predictive value, 0.92; accuracy, 0.94). Of the validated 10 markers, expression analysis of TFF3/PLAB/TG/ADM3/ HGD1/LGALS3 per sample was found to be the most discriminative combination and allowed correct classification in all benign tumors and in 37 of 46 thyroid malignancies (misclassification error rates: 0 and 0.20 for the benign and malignant entities, respectively). If toxic thyroid nodules were excluded from the analysis (because they may be identified by scintiscanning and may thus not need fine-needle aspiration cytology), the six-marker set correctly classified all benign samples and 42 of 46 thyroid cancers (sensitivity, 0.91; specificity, 1.0; positive predictive value 1.0; negative predictive value, 0.94; accuracy, 0.96).
Discussion
The aim of our study was to validate recently proposed markers (4, 6 -8, 11) for the differential diagnosis of thyroid nodular disease in a region with borderline iodine deficiency. Because the clinical manifestation of thyroid nodular disease is usually that of a visible, palpable, or increasingly (ultrasound diagnosed) incidental thyroid lesion but not of thyroid histopathology, we decided to use a broader (benign vs. malignant thyroid tumor) rather than entity focused (follicular adenoma vs. carcinoma) approach. In addition, in Germany most patients with nodular thyroid disease undergo scintiscanning, and FNAC analysis is usually restricted to cold thyroid nodules (14) , whereas abroad FNAC is advocated as the first diagnostic procedure in a patient with a euthyroid nodule (15) . Therefore, benign thyroid nodules with different functional entities were included in the study.
Our findings demonstrate that several markers previously identified through transcriptome analysis of follicular tumors from the United States (4, 7) and Japan (8, 13) , e.g. from populations with a different genetic and environmental background, can also be applied to discriminate thyroid specimen in a region with borderline iodine deficiency. This suggests that these markers are indeed disease specific. In addition, we found that combinations of markers not only allowed a distinction of follicular adenoma and carcinoma but also at the same time were suitable to separate the more heterogeneous entities of benign and ma- lignant thyroid tumors. However, our data also illustrate that the aim of a molecular discrimination of benign and malignant thyroid tumors is not the Holy Grail of a single marker gene, but in view of the heterogeneity of thyroid tumors, multiple marker sets need to be applied to reach this aim. In our tumor series a sixgene marker set comprising TFF3/PLAB/TG/ADM3/HGD1/ LGALS3 allowed the best prediction, i.e. 94% accuracy for the differentiation of benign thyroid lesions and thyroid cancer. The important next step will be to test independently validated gene sets, such as our or other marker sets, in multicenter trials on large series of thyroid tumors and their FNAC.
